Navigation Links
Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
Date:5/4/2009

) and Fovea holds an exclusive worldwide license to this intellectual property for ophthalmic indications.

"This study validates both a new clinical technology and new therapeutic approach," said Mark B. Abelson, M.D., Chairman and Chief Scientific Officer of Ora, Inc. "Patients with a history of chronic ocular background inflammation make up a large segment of the ocular allergy market, and are also patients that tend to evolve towards dry eye, another significant ocular disorder. In this study, they have been treated effectively and safely by Prednisporin(TM)."

Allergic conjunctivitis is a frequent disorder. It occurs in up to 90% of patients suffering from allergies and in more than 20% of the global population. In the USA alone, 80 million people experience ocular surface allergy and inflammation. More than 50% of all forms of allergic conjunctivitis have a chronic inflammatory background (persistent allergic conjunctivitis). As current therapies do not address the underlying chronic inflammation, they fail to treat such a disease effectively. Significant opportunities exist for novel products in the ocular allergy market.

Fovea is now preparing pivotal trials for Prednisporin(TM) both in the USA and in Europe with the goal of filing NDA applications late 2010.

About Fovea Pharmaceuticals

Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical company specialized in development and commercialization of drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Founded in May 2005, Fovea has raised euro 50.5m ($69m) in two financing rounds from a strong international syndicate of investors.

Fovea has built a project portfolio including internal research programs on dry AMD, glaucoma (neuroprotection) and retinal dystrophies as well as clinical programs underway for such indications as allergic conjunctivitis, di
'/>"/>

SOURCE Fovea Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug ... today announced that J.J. Finkelstein , chief executive ... overview at two upcoming investor conferences. ... Annual Microcap Conference on Thursday May 28, 2015 ... 11:00 am EDT.  A webcast will be available at ...
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, ... awarded CSL Behring its 2015 Corporate Leadership Award ... advancing science and improving the care of the bleeding disorders ... CEO and Managing Director, CSL Limited, during the NHF Annual ... on May 21. "The National Hemophilia Foundation is ...
(Date:5/22/2015)... -- The Mesothelioma Victims Center is incredibly passionate about ... best possible compensation, and they are also extremely focused ... caused by exposure to asbestos or their family ... options such as a recent possible medical breakthrough. For ... anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
(Date:5/24/2015)... A report out just last month ... option for avoiding cardiovascular disease is exercise and maintaining ... single most powerful predictor of death and survival, even ... family history of premature death -- a finding that ... fitness. , The Importance of Cardiovascular Screening , The ...
(Date:5/23/2015)... May 23, 2015 With the implementation ... are finding it increasingly difficult to provide their employees ... to provide adequate insurance for employees stand to face ... such an integral part of a business’s success or ... for businesses, Online USA Doctors has created a varying ...
(Date:5/23/2015)... May 23, 2015 A live auction will ... from hospitals, surgery centers and other medical facilities around the ... including endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... 27 and Thursday, May 28 starting at 9:00am CDT each ... 1400 N. 25th Avenue, Melrose Park, IL 60160. Anyone ...
(Date:5/22/2015)... Pasadena, Calif. (PRWEB) May 22, 2015 ... where technology, communication and capacity are intersecting to ... and across society, the opening speaker at WesternU's ... , California Lieut. Gov. Gavin Newsom, a former ... was the keynote speaker at the graduation ceremony ...
(Date:5/22/2015)... OH (PRWEB) May 22, 2015 River ... that Kyle Johnson, the health system’s Chief Financial Officer ... interests. Johnson has served as the company CFO since ... West will be joining the health system as CFO. ... an interim basis, while the Board of Trustees conducts ...
Breaking Medicine News(10 mins):Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2
... ... ... continuing to offer H1N1 nasal vaccines and H1N1 vaccine shots at four Centegra Primary Care (CPC) ... sites in Huntley, Woodstock, Crystal Lake and McHenry and will be open as follows: , ...
... , LA JOLLA, Calif., Dec. 3 ... Studies unanimously voted to elect three new members during its ... is co-founder and Managing Director of De Novo Ventures in Palo ... in early stage medical device and biotechnology companies. Dotzler founded Medicus ...
... , Research could lead to an ... known to result in cancer and genetic diseases , ... first time observed the movement of a single molecule of ... significantly, they have identified a previously unknown step that they ...
... primates , , THURSDAY, Dec. 3 (HealthDay News) -- A ... a primate study. , The drug, called SPC3649, uses a ... Unlike other antivirals that target the virus itself, the new ... that hepatitis C needs to replicate, the researchers explained. , ...
... , , CHICAGO, Dec. 3 ... medicine, called platelet-rich plasma therapy (PRP), is showing strong ... to a prominent dental researcher and editor of the ... James Rutkowski, DMD, PhD, reported at the recent annual ...
... Deutsches rzteblatt International contains the first scientific presentation ... virus (H1N1/09) in the German-speaking countries since the start ... the Dsseldorf University Hospital retrospectively evaluated data from a ... Dtsch Arztebl Int 2009; 106[47]: 770-6). Their medical-scientific ...
Cached Medicine News:Health News:Centegra H1N1 Vaccination Clinics Continue 2Health News:Centegra H1N1 Vaccination Clinics Continue 3Health News:Centegra H1N1 Vaccination Clinics Continue 4Health News:Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 3Health News:New Hepatitis C Treatment Shows Promise 2Health News:New Hepatitis C Treatment Shows Promise 3Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2
Curved shafts with serrated 1.5 mm upper and 2 mm lower jaws. Serrated cross action handle with slide lock and polished finish. Most popular size or model....
Folding forceps used for L161U. Manufactured in titanium....
Titanium. Thin jaws provide secure grasp of the folded lens for insertion into the eye. Reverse action forceps with angled shaft....
2.5 mm cups angled 50 degrees, 10 mm from angle to tip. Serrated handle with polished finish....
Medicine Products: